Leland Gershell
Stock Analyst at Oppenheimer
(4.48)
# 289
Out of 4,964 analysts
140
Total ratings
48.48%
Success rate
26.21%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $8 | $7.99 | +0.13% | 3 | Aug 8, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $28 → $32 | $18.56 | +72.41% | 6 | Aug 7, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $67.68 | +62.53% | 9 | Aug 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $60 → $61 | $49.59 | +23.01% | 3 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Outperform | $490 | $454.18 | +7.89% | 8 | Aug 4, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $20 | $4.85 | +312.37% | 1 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $76 → $110 | $102.30 | +7.53% | 2 | Jul 10, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $43 → $22 | $6.25 | +252.00% | 5 | Jun 23, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $215 → $224 | $193.23 | +15.92% | 12 | Jun 13, 2025 | |
| URGN UroGen Pharma | Maintains: Outperform | $10 → $31 | $19.54 | +58.65% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $2.29 | +337.64% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $707.96 | +0.01% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $1.56 | +541.03% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $8.00 | +150.00% | 3 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $58.66 | +67.06% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $24.21 | +114.79% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $3.29 | +1,419.76% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.25 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $15.16 | +249.60% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $4.34 | +591.24% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $2.12 | +466.04% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $3.24 | +154,220.99% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.23 | +673.99% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $30.40 | +140.13% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $2.87 | +596.86% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $20.19 | +43.64% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $9.65 | +262.69% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.83 | +1,111.24% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.28 | +1,462.50% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.77 | +634.46% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $4.23 | +2,736.88% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.38 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $18.05 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.23 | +2,142.15% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $15.47 | - | 5 | Mar 31, 2020 |
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $7.99
Upside: +0.13%
Viridian Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $18.56
Upside: +72.41%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $67.68
Upside: +62.53%
BridgeBio Pharma
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $49.59
Upside: +23.01%
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $454.18
Upside: +7.89%
Lexeo Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $4.85
Upside: +312.37%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $102.30
Upside: +7.53%
Capricor Therapeutics
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $6.25
Upside: +252.00%
Ascendis Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $193.23
Upside: +15.92%
UroGen Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $19.54
Upside: +58.65%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $2.29
Upside: +337.64%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $707.96
Upside: +0.01%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.56
Upside: +541.03%
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $8.00
Upside: +150.00%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $58.66
Upside: +67.06%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $24.21
Upside: +114.79%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $3.29
Upside: +1,419.76%
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.25
Upside: -
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $15.16
Upside: +249.60%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $4.34
Upside: +591.24%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.12
Upside: +466.04%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $3.24
Upside: +154,220.99%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.23
Upside: +673.99%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $30.40
Upside: +140.13%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $2.87
Upside: +596.86%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $20.19
Upside: +43.64%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $9.65
Upside: +262.69%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.83
Upside: +1,111.24%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.28
Upside: +1,462.50%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.77
Upside: +634.46%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $4.23
Upside: +2,736.88%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.38
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $18.05
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $2.23
Upside: +2,142.15%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $15.47
Upside: -